ACCESS PHARMACEUTICALS Explosionsgefahr?
Development team at Access Pharmaceuticals is interested in identifying out-licensing candidates, as well as alliance and merger opportunities for for our oncology and dermatology products, as well as for our nanopolymer technologies, including Cobalamin™ for oral drug delivery, Cobalamin™ for disease targeting, and SEPA, Access’ nail and transdermal drug delivery technology.
MuGard™ is our product for oral mucositis which has received US FDA marketing allowance. Access has licensing agreements with Milestone Biosciences (North America), SpePharm (Europe) and RHEI Pharmaceuticals (certain Asian territories), and is seeking commercial partners in other territories.
Access has exclusive worldwide rights to the oncology applications of phenylbutyrate (PB), a histone deacetylase (HDAC) inhibitor. Access is seeking licensing and commercialization partners for use of PB in cancer therapy and for the topical treatment of radiation proctitis.
ProLindac™ is our major chemotherapeutic compound, currently in Phase 2 clinical development. Access has licensed ProLindac to Nanjing Aosaikang Medicinal Group Co., Ltd for development and commercialization in China, and is seeking codevelopment partners for other territories.
Angiolix®, Alchemix®, and Prodrax® are anticancer products in preclinical development, while thiarabine is a novel nucleoside in phase 2 clinical development. Pexiganan is a phase 3 cream product for the treatment of diabetic foot ulcers and EcoNail is a phase 2 nail lacquer for treatment of onychomycosis.
We are open to discussing arrangements of all types. To learn more about our products and capabilities please contact Phillip Wise by sending an email to the address below.
interessante Pipeline!!!
Angehängte Grafik:
pipeline.jpg (verkleinert auf 87%)
pipeline.jpg (verkleinert auf 87%)
Jeffrey B. Davis, Chief Executive Officer
President, SCO Financial Group LLC.
Senior Vice President and Chief Financial Officer of a healthcare technology company.
Vice President, Corporate Finance, at Deutsche Morgan Grenfell.
Senior marketing and product management positions at AT&T Bell Laboratories.
Marketing and Product Manager at Philips Medical Systems North America.
MBA, The Wharton School, University of Pennsylvania.
BS Biomedical Engineering, Boston University.
ist President der SCO Financial Group
http://finance.yahoo.com/q/it?s=ACCP.OB
das Müssten die insider sein
MK ca 48 Mio Dollar
Shares ca 22 Mio
einfach mal anschauen!!! Cash sind wohl noch ca 2,7 Mille da? In Erwartung der Royaltis dürfte es aber allemal reichen!
http://suche.aol.de/aol/...amp;u=http%3A%2F%2Fwww.accesspharma.com%2F
Gruss Macos
https://www.docmorris.de/de/suche/produkte/...laschen/474079?filters=
dann müssten ja bald die ersten Zahlungen fliessen???
Was ist das denn fürn ne Bude???
das gefällt mir gar nicht!!!
http://suche.aol.de/aol/...334&u=http%3A%2F%2Fmilestonebio.com%2F
http://suche.aol.de/aol/...Finvestorsandmedia%2Freleases%2F021908.htm
ACCESS TO EVALUATE FURTHER DEVELOPMENT OUTSIDE HEMATOLOGICAL CANCERS
Press Release
Source: Access Pharmaceuticals, Inc.
On Tuesday July 7, 2009, 9:00 am EDT
Buzzed! Print
Companies:Access pharmaceuticals inc.
DALLAS, July 7 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP - News) announced today new preclinical data demonstrating that thiarabine shows remarkable efficacy in the prevention and treatment of rheumatoid arthritis (RA). In a well-established animal model for RA, an exceptional restoration of joint structure was observed in the studies, which were conducted at Wayne State University School of Medicine and at Southern Research Institute.
Related Quotes
Symbol Price Change
ACCP.OB 2.08 0.00
{"s" : "accp.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""} As a therapeutic treatment of established disease, thiarabine demonstrated a highly significant, dose-dependent amelioration of arthritis. Thiarabine treatment resulted in a broad inhibition of disease pathology, with reduction of both inflammatory and erosive disease parameters, as well as protection from loss of cartilage matrix proteins. When used as a preventative treatment, thiarabine blocked the development of joint disease at the 60 mg/kg/day dose level and exhibited a significant reduction in disease incidence and severity at 20 mg/kg/day.
In a therapeutic study comparing thiarabine to methotrexate, a commonly used clinical drug for RA treatment, high resolution 3-D images from an X-ray microtomograph were used along with histological scoring to evaluate joint and bone destruction. Thiarabine demonstrated statistically significant anti-arthritic efficacy comparable to that of methotrexate. "The images from X-ray microtomography present a compelling visual representation of diseased vs. treated limbs" commented David Nowotnik, Senior Vice President Research and Development. "We are delighted with the results of the preclinical study which demonstrate a real benefit to the use of thiarabine in RA."
"Our current development focus for thiarabine is for the treatment of hematological cancers," stated Jeffrey B. Davis, President & CEO. "But, we believe these new RA data provide compelling evidence that Thiarabine should be developed for rheumatoid arthritis as well."
Thiarabine is a next generation nucleoside analogue that Access has licensed from Southern Research. It has been in two Phase 1/2 solid tumor trials and was shown to have significant anti-tumor activity. Access is now working with leukemia and lymphoma specialists to initiate additional Phase 2 clinical trials in acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and other indications. "The IND for thiarabine has been transferred to Access and we have a supply of clinical-grade material." continued Dr. Nowotnik. "We should be able to start the study shortly after FDA clearance of the protocol and drug recertification."
Access is actively seeking co-development partners for all applications of Thiarabine.
About Access: Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
Contact: Company Contact: Investor Relations
Stephen B. Thompson Donald C. Weinberger/Diana Bittner (media)
Vice President Wolfe Axelrod Weinberger Assoc. LLC
Chief Financial Officer (212) 370-4500
Access Pharmaceuticals, Inc.
http://finance.yahoo.com/news/...-prnews-4208247497.html?x=0&.v=1
http://seekingalpha.com/article/...ine-shallow-valuation?source=yahoo
Access to Provide Details on MuGard Launch in Europe
http://finance.yahoo.com/news/...-prnews-2448465290.html?x=0&.v=1
PREVENTION OF ORAL MUCOSITIS EXPANDS MARKET POTENTIAL TO MULTIPLE BILLIONS OF DOLLARS
http://finance.yahoo.com/news/...-prnews-3941187419.html?x=0&.v=1
Wird Zeit das der Partner in US mal endlich loslegt, oder wie stellen sie sich das dort vor?
Optionen
| Boardmail an "Reise" |
Wertpapier: ACCESS PHARMACEUTICL |
Verdammt jetzt weiss ich nicht, was ich beim nächsten Rücksetzer kaufen soll.... Antigenics inc oder Genta oder Acces Pharmaceuticals????
Scheisse gibt ja mehr Pharmafirmen als Zecken=(
Mach weiter so richtig gut
Optionen
| Boardmail an "BioLogic" |
Wertpapier: ACCESS PHARMACEUTICL |
Ich wollte hier noch aufspringen aber jetzt lohnt es sich wahrscheinlich net mehr
grüße
Optionen
| Boardmail an "BioLogic" |
Wertpapier: ACCESS PHARMACEUTICL |
Money Flow und OBV sehen super aus.
Sammel bei Gelegenheit immer ein Paar ein.
Werde Acces weiterhin beobachten und Mugard im Auge behalten.
Danke schon mal
Optionen
| Boardmail an "BioLogic" |
Wertpapier: ACCESS PHARMACEUTICL |